ContextLogic Inc (LOGC)
NASDAQ: LOGC · IEX Real-Time Price · USD
6.00
-0.03 (-0.50%)
At close: Jul 19, 2024, 4:00 PM
6.03
+0.03 (0.50%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
ContextLogic Revenue
ContextLogic had revenue of $227.00M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $36.00M. In the year 2023, ContextLogic had annual revenue of $287.00M.
Revenue (ttm)
$227.00M
Revenue Growth
-52.51%
P/S Ratio
0.65
Revenue / Employee
$502,212
Employees
452
Market Cap
146.95M
Revenue Chart
* The company reports in USD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 287.00M | -284.00M | -49.74% |
Dec 31, 2022 | 571.00M | -1.51B | -72.61% |
Dec 31, 2021 | 2.09B | -456.00M | -17.95% |
Dec 31, 2020 | 2.54B | 640.00M | 33.67% |
Dec 31, 2019 | 1.90B | 173.00M | 10.01% |
Dec 31, 2018 | 1.73B | 627.00M | 56.95% |
Dec 31, 2017 | 1.10B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
RumbleON | 1.34B |
Tilly's | 615.30M |
Purple Innovation | 526.84M |
Niu Technologies | 380.45M |
The ONE Group Hospitality | 335.21M |
GrowGeneration | 216.94M |
Kewaunee Scientific | 203.76M |
Kandi Technologies Group | 123.60M |
LOGC News
- 1 year ago - Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics - Business Wire
- 1 year ago - LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates - PRNewsWire
- 1 year ago - LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC - Business Wire
- 1 year ago - INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGC - PRNewsWire
- 1 year ago - SHAREHOLDER ALERT: Weiss Law Investigates LogicBio Therapeutics, Inc. - PRNewsWire
- 1 year ago - Shareholder Alert: Ademi LLP investigates whether LogicBio® Therapeutics, Inc. has obtained a Fair Price in its transaction with AstraZeneca - PRNewsWire
- 1 year ago - LogicBio's stock skyrockets after buyout bid for a 667% premium - Market Watch
- 1 year ago - LOGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LogicBio Therapeutics, Inc. Is Fair to Shareholders - Business Wire